{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:48:10Z","timestamp":1787845690525,"version":"build-2784847793"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Acute severe ulcerative colitis (ASUC) is a high-risk condition associated with intense inflammation and a substantial risk of early colectomy. Intravenous steroids (IVS) remain the first-line therapy; however, steroid nonresponse is common. While the C-reactive protein-to-albumin ratio (CAR) has been proposed as a prognostic marker, data on its dynamic changes and late-phase performance remain limited. This study aimed to evaluate the serial performance of albumin and CAR at days 3 and 7 and to assess their association with early and delayed steroid response in a real-world cohort of biologic-naive ASUC patients. Methods: Biologic-naive patients hospitalized with ASUC between 2010 and 2023 were retrospectively analyzed. Disease severity and treatment response were defined using Truelove\u2013Witts and Oxford criteria. Clinical and biochemical parameters, including albumin, CAR, and neutrophil-to-lymphocyte ratio (NLR), were assessed at baseline and on days 3 and 7. Associations with steroid response were evaluated using ROC analysis and multivariable logistic regression. Results: Ninety-eight patients were included. The IVS response rate was 11.2% on day 3 and 56.1% by day 7. Among nonresponders, 25% required infliximab rescue therapy, and colectomy occurred in 12.2%. Although day 3 CAR showed a trend toward discrimination, this did not reach statistical significance (p = 0.098) and should be considered exploratory. By day 7, responders had significantly higher albumin levels and lower CAR values (p &lt; 0.05). Albumin (AUC = 0.702) and CAR (AUC = 0.713) demonstrated comparable performance. In multivariable analyses, day 7 albumin and CAR were significantly associated with steroid response, whereas NLR was not associated. Conclusions: Albumin and CAR are clinically relevant biomarkers associated with steroid response in ASUC. Early changes, particularly in CAR, may provide preliminary signals of nonresponse but require cautious interpretation. In contrast, day 7 measurements appear to reflect ongoing inflammatory dynamics and treatment evolution rather than true baseline predictors. Serial assessment of these biomarkers may support treatment monitoring and help optimize the timing of rescue therapy.<\/jats:p>","DOI":"10.3390\/jcm15072730","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:06:21Z","timestamp":1775441181000},"page":"2730","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Utility of Albumin and the C-Reactive Protein-to-Albumin Ratio for Predicting Intravenous Steroid Response in Acute Severe Ulcerative Colitis"],"prefix":"10.3390","volume":"15","author":[{"given":"Sayar","family":"S\u00fcleyman","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, VM Medical Park Pendik Hospital, 34899 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pala","family":"Emin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sancaktepe \u0130lhan Varank Training and Research Hospital, 34785 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-8115","authenticated-orcid":false,"given":"Aykut","family":"H\u00fcseyin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, \u00dcmraniye Training and Research Hospital, 34764 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ak","family":"\u00c7a\u011fatay","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, VM Medical Park Pendik Hospital, 34899 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7288-3936","authenticated-orcid":false,"given":"\u00d6lmez","family":"\u015eehmus","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University of Health Sciences, Adana City Training and Research Hospital, 01240 Adana, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zdil","family":"Kamil","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Memorial Ata\u015fehir Hospital, 34758 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"San, E.O.M., Sharif, K., Rosiou, K., Rennie, M., and Selinger, C.P. (2024). Recent Advances in the Management of Acute Severe Ulcerative Colitis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237446"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"jjaf131","DOI":"10.1093\/ecco-jcc\/jjaf131","article-title":"Day 3 Oxford criteria predict steroid non-response for acute severe ulcerative colitis in the post biologic era","volume":"19","author":"Vuyyuru","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_4","first-page":"458","article-title":"Systematic Review: Outcome Prediction in Acute Severe Ulcerative Colitis","volume":"36","author":"Angkeow","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br. Med. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"key":"ref_7","first-page":"49","article-title":"A practical marker to determining acute severe ulcerative colitis: CRP\/albumin ratio","volume":"7","author":"Sayar","year":"2019","journal-title":"North. Clin. Istanb."},{"key":"ref_8","first-page":"1203","article-title":"Neutrophil\u2013Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis","volume":"60","author":"Celikbilek","year":"2014","journal-title":"Clin. Lab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European Evidence-based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1","volume":"6","author":"Dignass","year":"2012","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis","volume":"11","author":"Harbord","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of IBD","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin vs infliximab in patients with severe ulcerative colitis refractory to steroids","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"48487","DOI":"10.1074\/jbc.R400025200","article-title":"C-reactive Protein","volume":"279","author":"Black","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in IBD: Useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e000662","DOI":"10.1136\/bmjgast-2021-000662","article-title":"Effect of disease duration on the association between serum albumin and mucosal healing in patients with ulcerative colitis","volume":"8","author":"Yagi","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: Development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"Ho","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/jgh.16895","article-title":"Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future","volume":"40","author":"Cameron","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/MCG.0000000000000884","article-title":"CRP\/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis","volume":"52","author":"Gibson","year":"2018","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ranzani, O.T., Zampieri, F.G., Forte, D.N., Azevedo, L.C., and Park, M. (2013). C-reactive protein\/albumin ratio predicts 90-day mortality of septic patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059321"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1499-3872(17)60007-9","article-title":"Predictive value of C-reactive protein\/albumin ratio in acute pancreatitis","volume":"16","author":"Kaplan","year":"2017","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e19165","DOI":"10.1097\/MD.0000000000019165","article-title":"The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis","volume":"99","author":"Cui","year":"2020","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20440","article-title":"Comparison of infliximab and ciclosporin in steroid-resistant ulcerative colitis: Pragmatic randomised trial and economic evaluation (CONSTRUCT)","volume":"20","author":"Williams","year":"2016","journal-title":"Health Technol. Assess."},{"key":"ref_31","first-page":"197","article-title":"The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: A retrospective cohort study","volume":"115","year":"2023","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000520523","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as noninvasive predictors of the therapeutic outcomes of systemic corticosteroid therapy in ulcerative colitis","volume":"6","author":"Endo","year":"2021","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12664-013-0372-8","article-title":"Infliximab in Patients with Severe Steroid-Refractory Ulcerative Colitis: Indian Experience","volume":"33","author":"Sood","year":"2014","journal-title":"Indian J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3748\/wjg.v19.i7.1091","article-title":"Efficacy of Infliximab in Acute Severe Ulcerative Colitis: A Real-World Clinical Experience","volume":"19","author":"Halpin","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.dld.2008.03.014","article-title":"Colectomy Rate in Acute Severe Ulcerative Colitis in the Era of Rescue Therapy","volume":"40","author":"Aratari","year":"2008","journal-title":"Dig. Liver Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2730\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:34:58Z","timestamp":1775442898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072730"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072730","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]}}}